Cargando…

Long‐Term Effects of Sglt2 Deletion on Bone and Mineral Metabolism in Mice

Sodium‐glucose cotransporter 2 (SGLT2) inhibitors improve kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM). However, bone fragility has emerged as a side effect in some but not in all human studies. Because use of SGLT2 inhibitors in humans affects mineral metaboli...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerber, Claire, Wang, Xueyan, David, Valentin, Quaggin, Susan E., Isakova, Tamara, Martin, Aline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328801/
https://www.ncbi.nlm.nih.gov/pubmed/34368611
http://dx.doi.org/10.1002/jbm4.10526
_version_ 1783732375056809984
author Gerber, Claire
Wang, Xueyan
David, Valentin
Quaggin, Susan E.
Isakova, Tamara
Martin, Aline
author_facet Gerber, Claire
Wang, Xueyan
David, Valentin
Quaggin, Susan E.
Isakova, Tamara
Martin, Aline
author_sort Gerber, Claire
collection PubMed
description Sodium‐glucose cotransporter 2 (SGLT2) inhibitors improve kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM). However, bone fragility has emerged as a side effect in some but not in all human studies. Because use of SGLT2 inhibitors in humans affects mineral metabolism, we investigated the long‐term effects of genetic loss of Sglt2 function on bone and mineral metabolism in mice. Slc5a2 nonsense mutation in Sweet Pee (SP) mice results in total loss of Sglt2 function. We collected urine, serum, and bone samples from 15‐week‐old and 25‐week‐old wild‐type (WT) and SP mice fasted from food overnight. We measured parameters of renal function and mineral metabolism and we assessed bone growth, microarchitecture, and mineralization. As expected, 15‐week‐old and 25‐week‐old SP mice showed increased glucosuria, and normal kidney function compared to age‐matched WT mice. At 15 weeks, SP mice did not show alterations in mineral metabolism parameters. At 25 weeks, SP mice showed reduced fasting 24‐hour urinary calcium excretion and increased fractional excretion of phosphate, but normal serum calcium and phosphate, parathyroid hormone (PTH), vitamin D (1,25(OH)(2)D), and fibroblast growth factor (FGF23) levels. At 25 weeks, but not at 15 weeks, SP mice showed reduced body weight compared to WT. This was associated with reduced femur length at 25 weeks, suggesting impaired skeletal growth. SP mice did not show trabecular or cortical bone microarchitectural modifications but showed reduced cortical bone mineral density compared to WT mice at 25 weeks. These results suggest that loss of Sglt2 function in mice in the absence of T2DM does not alter regulatory hormones FGF23, PTH, and 1,25(OH)(2)D, but may contribute to bone fragility over the long term. Future studies are required to determine how loss of Sglt2 function impacts bone fragility in T2DM. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
format Online
Article
Text
id pubmed-8328801
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-83288012021-08-06 Long‐Term Effects of Sglt2 Deletion on Bone and Mineral Metabolism in Mice Gerber, Claire Wang, Xueyan David, Valentin Quaggin, Susan E. Isakova, Tamara Martin, Aline JBMR Plus Original Articles Sodium‐glucose cotransporter 2 (SGLT2) inhibitors improve kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM). However, bone fragility has emerged as a side effect in some but not in all human studies. Because use of SGLT2 inhibitors in humans affects mineral metabolism, we investigated the long‐term effects of genetic loss of Sglt2 function on bone and mineral metabolism in mice. Slc5a2 nonsense mutation in Sweet Pee (SP) mice results in total loss of Sglt2 function. We collected urine, serum, and bone samples from 15‐week‐old and 25‐week‐old wild‐type (WT) and SP mice fasted from food overnight. We measured parameters of renal function and mineral metabolism and we assessed bone growth, microarchitecture, and mineralization. As expected, 15‐week‐old and 25‐week‐old SP mice showed increased glucosuria, and normal kidney function compared to age‐matched WT mice. At 15 weeks, SP mice did not show alterations in mineral metabolism parameters. At 25 weeks, SP mice showed reduced fasting 24‐hour urinary calcium excretion and increased fractional excretion of phosphate, but normal serum calcium and phosphate, parathyroid hormone (PTH), vitamin D (1,25(OH)(2)D), and fibroblast growth factor (FGF23) levels. At 25 weeks, but not at 15 weeks, SP mice showed reduced body weight compared to WT. This was associated with reduced femur length at 25 weeks, suggesting impaired skeletal growth. SP mice did not show trabecular or cortical bone microarchitectural modifications but showed reduced cortical bone mineral density compared to WT mice at 25 weeks. These results suggest that loss of Sglt2 function in mice in the absence of T2DM does not alter regulatory hormones FGF23, PTH, and 1,25(OH)(2)D, but may contribute to bone fragility over the long term. Future studies are required to determine how loss of Sglt2 function impacts bone fragility in T2DM. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research. John Wiley & Sons, Inc. 2021-07-06 /pmc/articles/PMC8328801/ /pubmed/34368611 http://dx.doi.org/10.1002/jbm4.10526 Text en © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Gerber, Claire
Wang, Xueyan
David, Valentin
Quaggin, Susan E.
Isakova, Tamara
Martin, Aline
Long‐Term Effects of Sglt2 Deletion on Bone and Mineral Metabolism in Mice
title Long‐Term Effects of Sglt2 Deletion on Bone and Mineral Metabolism in Mice
title_full Long‐Term Effects of Sglt2 Deletion on Bone and Mineral Metabolism in Mice
title_fullStr Long‐Term Effects of Sglt2 Deletion on Bone and Mineral Metabolism in Mice
title_full_unstemmed Long‐Term Effects of Sglt2 Deletion on Bone and Mineral Metabolism in Mice
title_short Long‐Term Effects of Sglt2 Deletion on Bone and Mineral Metabolism in Mice
title_sort long‐term effects of sglt2 deletion on bone and mineral metabolism in mice
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328801/
https://www.ncbi.nlm.nih.gov/pubmed/34368611
http://dx.doi.org/10.1002/jbm4.10526
work_keys_str_mv AT gerberclaire longtermeffectsofsglt2deletiononboneandmineralmetabolisminmice
AT wangxueyan longtermeffectsofsglt2deletiononboneandmineralmetabolisminmice
AT davidvalentin longtermeffectsofsglt2deletiononboneandmineralmetabolisminmice
AT quagginsusane longtermeffectsofsglt2deletiononboneandmineralmetabolisminmice
AT isakovatamara longtermeffectsofsglt2deletiononboneandmineralmetabolisminmice
AT martinaline longtermeffectsofsglt2deletiononboneandmineralmetabolisminmice